STOCK TITAN
  1. Home
  2. Sec-filings
  3. CNO
  4. [Form 4] CNO Financial Group, Inc. Insider Trading Activity

CNO Financial exec sells 24,674 shares after exercise

A CNO Financial Group division president exercised 15,000 options and sold 24,674 shares under a pre‑arranged Rule 10b5‑1 trading plan.

Filing Impact
(Very High)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

CNO Financial Group, Inc. (CNO) reports that Karen J. DeToro, President of the Worksite Division, exercised stock options and sold shares of common stock. On August 31 and September 1, 2026, she exercised options covering 15,000 shares at an exercise price of $15.83 per share, receiving common stock. Between August 31 and September 2, 2026, she sold an aggregate of 24,674 shares of common stock in open-market transactions at weighted average prices around the mid‑$54 to mid‑$55 range, including 5,964 shares at $55.1188 per share on September 2, 2026. All reported sales were made pursuant to a Rule 10b5‑1 trading plan adopted on May 11, 2026.

Positive

  • None.

Negative

  • None.

Insights

Analyzing...

Insider DeToro Karen J.
Role President, Worksite Division
Sold 24,674 shs ($1.36M)
Approx. gross sale proceeds $1.36M
Approx. exercise cost $237K
Type Security Shares Price Value
Sale Common Stock F1, F5 5,964 $55.1188 $329K
Exercise Employee Stock Option (Right to Buy) F6 7,500 $0.00 $0.00
Sale Common Stock F1, F3 1,836 $54.7301 $100K
Exercise Common Stock 7,500 $15.83 $119K
Sale Common Stock F1, F4 7,500 $54.7358 $411K
Exercise Employee Stock Option (Right to Buy) F6 7,500 $0.00 $0.00
Sale Common Stock F1, F2 1,874 $54.9805 $103K
Exercise Common Stock 7,500 $15.83 $119K
Sale Common Stock F1, F2 7,500 $54.9777 $412K
Holdings After Transaction: Employee Stock Option (Right to Buy) — 34,430 contracts (Direct); Common Stock — 36,450 shares (Direct)
Footnotes (6)
  1. F1. Shares sold pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026.
  2. F2. Reflects the weighted average sale price. For each of these two transactions, shares were sold at prices ranging from $54.855 per share to $55.36 per share. Reporting person will provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer or any security holder of the issuer.
  3. F3. Reflects the weighted average sale price. Shares were sold at prices ranging from $54.415 per share to $55.12 per share. Reporting person will provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer or any security holder of the issuer.
  4. F4. Reflects the weighted average sale price. Shares were sold at prices ranging from $54.415 per share to $55.13 per share. Reporting person will provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer or any security holder of the issuer.
  5. F5. Reflects the weighted average sale price. Shares were sold at prices ranging from $54.56 per share to $55.48 per share. Reporting person will provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer or any security holder of the issuer.
  6. F6. One-half of the stock options vested and became exercisable on September 30, 2021, and one-half vested and became exercisable on September 30, 2022.
Shares sold 24,674 shares Aggregate common shares sold in reported transactions between August 31 and September 2, 2026
Options exercised 15,000 shares Total shares underlying stock options exercised on August 31 and September 1, 2026
Option exercise price $15.83 per share Exercise price for the employee stock options converted into common stock
Sale price on September 2, 2026 $55.1188 per share Price for sale of 5,964 common shares on September 2, 2026
Weighted average sale prices $54.9805, $54.9777, $54.7301, $54.7358 per share Weighted average prices for various open‑market sales on August 31 and September 1, 2026
Rule 10b5-1 plan adoption date May 11, 2026 Date the trading plan governing the reported sales was adopted
Option expiration date September 30, 2029 Expiration date for the employee stock options that were exercised
Rule 10b5-1 trading plan regulatory
"Shares sold pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
weighted average sale price financial
"Reflects the weighted average sale price."
Employee Stock Option financial
"Employee Stock Option (Right to Buy)"
An employee stock option is a promise that lets a worker buy company shares later at a predetermined price, often after they stay for a certain period or meet performance goals — think of it like a coupon that locks in today's price for a future purchase. It matters to investors because options align employees’ incentives with company performance, can increase the number of shares outstanding (dilution) when exercised, and represent a compensation cost that affects reported profits and shareholder value.
vesting financial
"One-half of the stock options vested and became exercisable on September 30, 2021"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

What did CNO (CNO) executive Karen J. DeToro report in this Form 4?
She reported exercising 15,000 stock options at $15.83 per share and selling 24,674 shares of CNO common stock in open‑market transactions between August 31 and September 2, 2026, under a Rule 10b5‑1 trading plan.

How many CNO (CNO) shares did the insider sell and over what dates?
She sold a total of 24,674 shares of CNO common stock in multiple open‑market sales on August 31, 2026, September 1, 2026, and September 2, 2026, at weighted average prices in the mid‑$54 to mid‑$55 range.

Were the CNO (CNO) insider sales made under a Rule 10b5-1 plan?
Yes. The filing states the shares were sold pursuant to a Rule 10b5‑1 trading plan adopted on May 11, 2026, indicating the trades were pre‑arranged under that plan.

What options did the CNO (CNO) executive exercise in this filing?
She exercised stock options for 15,000 shares of CNO common stock at an exercise price of $15.83 per share. These options were originally scheduled to expire on September 30, 2029 and had fully vested by September 30, 2022.

What prices were received for the CNO (CNO) stock sales reported?
Reported weighted average sale prices include $54.9805, $54.9777, $54.7301, and $54.7358 per share, plus a sale of 5,964 shares at $55.1188 per share on September 2, 2026, with detailed price ranges disclosed in the footnotes.

What is Karen J. DeToro’s role at CNO (CNO) as noted in the filing?
She is identified as an officer of CNO Financial Group, Inc., serving as President, Worksite Division, and is the reporting person for the option exercises and share sales disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
DeToro Karen J.
(Last)(First)(Middle)
C/O CNO FINANCIAL GROUP, INC.
11299 ILLINOIS STREET, SUITE 200
(Street)
CARMEL INDIANA 46032
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
CNO Financial Group, Inc. [ CNO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
President, Worksite Division
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock08/31/2026S1,874(1)D$54.9805(2)44,250D
Common Stock08/31/2026M7,500A$15.8351,750D
Common Stock08/31/2026S7,500(1)D$54.9777(2)44,250D
Common Stock09/01/2026S1,836(1)D$54.7301(3)42,414D
Common Stock09/01/2026M7,500A$15.8349,914D
Common Stock09/01/2026S7,500(1)D$54.7358(4)42,414D
Common Stock09/02/2026S5,964(1)D$55.1188(5)36,450D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Employee Stock Option (Right to Buy)$15.8308/31/2026M7,500 (6)09/30/2029Common Stock7,500$041,930D
Employee Stock Option (Right to Buy)$15.8309/01/2026M7,500 (6)09/30/2029Common Stock7,500$034,430D
Explanation of Responses:
1. Shares sold pursuant to a Rule 10b5-1 trading plan adopted on May 11, 2026.
2. Reflects the weighted average sale price. For each of these two transactions, shares were sold at prices ranging from $54.855 per share to $55.36 per share. Reporting person will provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer or any security holder of the issuer.
3. Reflects the weighted average sale price. Shares were sold at prices ranging from $54.415 per share to $55.12 per share. Reporting person will provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer or any security holder of the issuer.
4. Reflects the weighted average sale price. Shares were sold at prices ranging from $54.415 per share to $55.13 per share. Reporting person will provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer or any security holder of the issuer.
5. Reflects the weighted average sale price. Shares were sold at prices ranging from $54.56 per share to $55.48 per share. Reporting person will provide full information regarding the number of shares sold at each separate price upon request by the SEC staff, the issuer or any security holder of the issuer.
6. One-half of the stock options vested and became exercisable on September 30, 2021, and one-half vested and became exercisable on September 30, 2022.
Remarks:
Heidi M. Krings, Attorney-in-Fact09/02/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR